IL213411A - Localized steroids and their use in radiation and chemotherapy injuries - Google Patents

Localized steroids and their use in radiation and chemotherapy injuries

Info

Publication number
IL213411A
IL213411A IL213411A IL21341111A IL213411A IL 213411 A IL213411 A IL 213411A IL 213411 A IL213411 A IL 213411A IL 21341111 A IL21341111 A IL 21341111A IL 213411 A IL213411 A IL 213411A
Authority
IL
Israel
Prior art keywords
radiation
topically active
active steroids
chemotherapeutic injury
chemotherapeutic
Prior art date
Application number
IL213411A
Other languages
English (en)
Hebrew (he)
Other versions
IL213411A0 (en
Inventor
B Mcdonald George
N Brey Robert
Schaber Christopher
Original Assignee
B Mcdonald George
Soligenix Inc
N Brey Robert
Schaber Christopher
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by B Mcdonald George, Soligenix Inc, N Brey Robert, Schaber Christopher filed Critical B Mcdonald George
Publication of IL213411A0 publication Critical patent/IL213411A0/en
Publication of IL213411A publication Critical patent/IL213411A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Inorganic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
IL213411A 2008-12-08 2011-06-06 Localized steroids and their use in radiation and chemotherapy injuries IL213411A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12078508P 2008-12-08 2008-12-08
PCT/US2009/067199 WO2010077681A1 (en) 2008-12-08 2009-12-08 Topically active steroids for use in radiation and chemotherapeutics injury

Publications (2)

Publication Number Publication Date
IL213411A0 IL213411A0 (en) 2011-07-31
IL213411A true IL213411A (en) 2016-12-29

Family

ID=42310112

Family Applications (1)

Application Number Title Priority Date Filing Date
IL213411A IL213411A (en) 2008-12-08 2011-06-06 Localized steroids and their use in radiation and chemotherapy injuries

Country Status (12)

Country Link
US (3) US20100183749A1 (enExample)
EP (2) EP2373160B1 (enExample)
JP (2) JP5709266B2 (enExample)
KR (2) KR20110092351A (enExample)
CN (2) CN106692162A (enExample)
AU (1) AU2009333538B2 (enExample)
CA (1) CA2745930C (enExample)
DK (2) DK2902031T3 (enExample)
IL (1) IL213411A (enExample)
NZ (1) NZ593694A (enExample)
SG (2) SG10201704531XA (enExample)
WO (1) WO2010077681A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889635B2 (en) 2008-09-30 2014-11-18 The Regents Of The University Of Michigan Dendrimer conjugates
US9017644B2 (en) 2008-11-07 2015-04-28 The Regents Of The University Of Michigan Methods of treating autoimmune disorders and/or inflammatory disorders
HUE062459T2 (hu) 2009-02-03 2023-11-28 Koninklijke Nederlandse Akademie Van Wetenschappen Tenyésztõközeg epiteliális õssejtek és az epiteliális õssejteket tartalmazó organoidok részére
US9752124B2 (en) 2009-02-03 2017-09-05 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium for epithelial stem cells and organoids comprising the stem cells
EP2412800A1 (en) 2010-07-29 2012-02-01 Koninklijke Nederlandse Akademie van Wetenschappen Liver organoid, uses thereof and culture method for obtaining them
WO2011059586A2 (en) 2009-10-30 2011-05-19 The Regents Of The University Of Michigan Multifunctional small molecules
US9381187B2 (en) * 2011-02-16 2016-07-05 Paloma Pharmaceuticals, Inc. Radiation countermeasure agents
WO2013085718A1 (en) 2011-12-08 2013-06-13 The Regents Of The University Of Michigan Multifunctional small molecules
DK2854850T3 (da) * 2012-05-25 2021-08-30 Sloan Kettering Inst Cancer Res Sammensætninger til behandling eller forebyggelse af strålingssygdom og gi-syndrom
WO2014025832A1 (en) * 2012-08-06 2014-02-13 University Of Southern California Wnt modulators for the protection, mitigation and treatment of radiation injury
WO2014059068A1 (en) * 2012-10-11 2014-04-17 The Trustees Of The University Of Pennsylvania Methods for the treatment and prevention of osteoporosis and bone-related disorders
WO2014134038A1 (en) * 2013-02-28 2014-09-04 The Regents Of The University Of Michigan Compositions and methods relating to induction of intestinal stem cell homeogenesis and/or regeneration
US11311598B2 (en) 2013-09-13 2022-04-26 Soligenix, Inc. Peptides and analogs for use in the treatment of oral mucositis
EP3044229B1 (en) 2013-09-13 2023-10-04 Soligenix, Inc. Peptides for use in the treatment of oral mucositis
US9439947B2 (en) 2014-03-28 2016-09-13 Albert Einstein College Of Medicine, Inc. Therapy for radiation-induced lung injury
JP6865679B2 (ja) * 2014-10-02 2021-04-28 サイトソーベンツ・コーポレーション 放射線で誘発された粘膜炎、食道炎、小腸炎、大腸炎、及び胃腸管急性放射線症候群を予防又は治療するための胃腸管投与多孔質消化管吸着剤ポリマーの使用
WO2017011457A1 (en) * 2015-07-12 2017-01-19 The University Of Tennessee Research Foundation Compositions and methods for protecting colonic epithelial barrier function
WO2017119988A2 (en) * 2015-12-10 2017-07-13 Memorial Sloan Kettering Cancer Center Radioprotection by wnt activation
CN107753932A (zh) * 2016-08-22 2018-03-06 中国辐射防护研究院 Kgf在制备治疗或预防放射性肠炎药物中的用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4661509A (en) * 1982-09-28 1987-04-28 Gordon Arnold Z Methods for treating leukopenia
US5252333A (en) * 1987-04-27 1993-10-12 Scotia Holdings Plc Lithium salt-containing pharmaceutical compositions
US6077692A (en) * 1995-02-14 2000-06-20 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US20030144202A1 (en) * 1996-10-15 2003-07-31 Amgen Inc. Uses of keratinocyte growth factor-2
WO2001024812A1 (en) * 1999-10-06 2001-04-12 N.V. Nutricia USE OF TRANSFORMING GROWTH FACTOR β AND GROWTH FACTORS IN THE TREATMENT AND PREVENTION OF DISEASES OF THE INTESTINAL MUCOSA
US20020086857A1 (en) * 2000-09-15 2002-07-04 Mcdonald George B. Method of long-term treatment of graft-versus-host disease using topical active corticosterioids
US7544348B2 (en) * 2001-02-15 2009-06-09 Access Pharmaceuticals, Inc. Liquid formulations for the prevention and treatment of mucosal diseases and disorders
EP1392321B1 (en) * 2001-03-15 2010-08-18 Soligenix, Inc. Method of treating inflammatory disorders of the gastrointestinal tract using topical active corticosteroids
US20060252735A1 (en) * 2004-12-30 2006-11-09 Dor Biopharma, Inc. Treatment of graft-versus-host disease and leukemia with beclomethasone dipropionate and prednisone
JP4839436B2 (ja) * 2005-11-02 2011-12-21 国立大学法人徳島大学 消化管粘膜保護剤、カベオリン遺伝子発現促進剤及び抗ストレス剤
US20070293458A1 (en) 2006-06-16 2007-12-20 Ip-6 Research Inc. Prevention of nuclear, solar, and other radiation-induced tissue damage
WO2008101215A1 (en) * 2007-02-16 2008-08-21 Varian Medical Systems Technologies, Inc. Preparative regimen for engraftment, growth and differentiation of non-hematopoeitic cells in vivo
EP3354276B1 (en) * 2007-11-13 2020-01-01 Meritage Pharma, Inc. Compositions for the treatment of gastrointestinal inflammation

Also Published As

Publication number Publication date
AU2009333538B2 (en) 2014-09-11
CN102307466A (zh) 2012-01-04
WO2010077681A1 (en) 2010-07-08
US20200155571A1 (en) 2020-05-21
EP2373160B1 (en) 2017-10-25
SG10201704531XA (en) 2017-07-28
CA2745930C (en) 2017-05-02
KR101783577B1 (ko) 2017-09-29
DK2902031T3 (en) 2019-01-14
HK1207582A1 (en) 2016-02-05
KR20170001735A (ko) 2017-01-04
EP2373160A4 (en) 2012-06-13
EP2902031B1 (en) 2018-10-24
JP2015038155A (ja) 2015-02-26
NZ593694A (en) 2013-09-27
US20170333448A1 (en) 2017-11-23
KR20110092351A (ko) 2011-08-17
DK2373160T3 (en) 2018-01-02
CA2745930A1 (en) 2010-07-08
JP2012511034A (ja) 2012-05-17
AU2009333538A1 (en) 2011-07-14
CN106692162A (zh) 2017-05-24
US20100183749A1 (en) 2010-07-22
IL213411A0 (en) 2011-07-31
JP5709266B2 (ja) 2015-04-30
JP5905562B2 (ja) 2016-04-20
EP2373160A1 (en) 2011-10-12
EP2902031A1 (en) 2015-08-05
SG171997A1 (en) 2011-07-28

Similar Documents

Publication Publication Date Title
IL213411A (en) Localized steroids and their use in radiation and chemotherapy injuries
IL254369B (en) Protects the vehicle and structure
GB2443823B (en) Devices and methods for use in construction
IL218169A (en) Quinazoline compounds and their pharmaceutical compositions containing them for use in therapy
GB201018014D0 (en) Analytical methods and arrays for use in the same
ZA201007309B (en) Topical combinations comprising an antimycotic and an antiviral agent
IL226800A0 (en) Dosage and administration for the prevention of cardiac toxicity in the treatment of 2erbb-targeted immunoliposomes containing the chemotherapy agents anthracycline
IL226168A0 (en) An auxiliary unit for conveyance and a method of using it
GB0921803D0 (en) Drug composition and its use in therapy
IL219768A0 (en) Drug combination with thebromine and its use in therapy
PL2367575T3 (pl) Kompozycja i opatrunek z tlenkiem azotu
IL219769A0 (en) Drug combination with theromine and its use in therapy
PL2543360T3 (pl) Bicele zakapsułkowane w liposomach i ich zastosowanie w rozcieńczonych układach
GB0921805D0 (en) Drug composition and its use in therapy
GB0910375D0 (en) Drug composition and its use in therapy
PL2313442T3 (pl) Środki dyspergujące i ich zastosowanie
PL2110241T3 (pl) Materiał kompozytowy, zwłaszcza do elementów zapinających pieluchy, o wysokiej rozciągliwości i właściwościach półelastycznych
EP2539033A4 (en) JET ASSEMBLY FOR USE IN DETECTORS AND OTHER DEVICES
EP2498606A4 (en) TIVOZANIB AND TEMSIROLIMUS IN COMBINATION
GB2462721B (en) Extendable and retractable clamp
TWM390691U (en) Caster device and luggage having the caster device
GB0900329D0 (en) Improvements in anti-ligature devices and methods
ZA201006197B (en) Fence and clamp for use in the fence
GB0909640D0 (en) Improvements in pushchairs and like mechanisms
GB0819103D0 (en) Raphaine compounds and their use in therapy

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed